用聚合物胶束选择性靶向肿瘤相关的巨噬细胞和肿瘤细胞，以增强癌症的化学免疫疗法。,Journal of Controlled Release

当前位置： X-MOL 学术 › J. Control. Release › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

用聚合物胶束选择性靶向肿瘤相关的巨噬细胞和肿瘤细胞，以增强癌症的化学免疫疗法。
Journal of Controlled Release ( IF 10.5 ) Pub Date : 2019-10-16 , DOI: 10.1016/j.jconrel.2019.09.021
Xiao Wei ₁ , Lingqiao Liu ₁ , Xilin Li ₁ , Yi Wang ₁ , Xing Guo ₁ , Jingya Zhao ₁ , Shaobing Zhou ₁

Affiliation

肿瘤相关巨噬细胞（TAM）相关的免疫疗法是一种非常有前途的策略，其中涉及用免疫调节剂咪喹莫特（R837）改变免疫抑制性肿瘤微环境以增强癌症治疗。然而，由于水溶性差和缺乏靶向能力，R837的功能受到严重限制。在这里，我们开发了两种靶向聚合物胶束，分别通过肿瘤内注射和静脉内注射将R837和抗癌药阿霉素（DOX）分别递送至TAM和肿瘤细胞，以增强针对乳腺癌的癌症化学免疫疗法。这些胶束在肿瘤组织中积累后，免疫刺激胶束释放R837，该R837与TAM内溶酶体膜上的TLR-7受体结合，从而刺激TAM的成熟，从而引起抗肿瘤免疫应答并减轻肿瘤微环境中的免疫抑制作用。同时，化学治疗胶束在肿瘤细胞的细胞质中释放DOX，直接诱导细胞死亡。结果，通过这些纳米药物实现了化学疗法和免疫疗法的协同组合，其分别激活了抗肿瘤免疫应答并抑制了肿瘤细胞的生长。因此，该策略是开发靶向纳米药物以针对恶性肿瘤的联合化学免疫疗法的新途径。通过这些纳米药物实现了化学疗法和免疫疗法的协同结合，它们分别激活了抗肿瘤免疫反应并抑制了肿瘤细胞的生长。因此，该策略是开发靶向纳米药物以针对恶性肿瘤的联合化学免疫疗法的新途径。通过这些纳米药物实现了化学疗法和免疫疗法的协同结合，它们分别激活了抗肿瘤免疫反应并抑制了肿瘤细胞的生长。因此，该策略是开发靶向纳米药物以针对恶性肿瘤的联合化学免疫疗法的新途径。

"点击查看英文标题和摘要"

Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.

Tumor-associated macrophage (TAM)-related immunotherapy is a greatly promising strategy that involves altering the immunosuppressive tumor microenvironment with the immunomodulator imiquimod (R837) for enhanced cancer therapy. However, the function of R837 is seriously limited due to poor water solubility and a lack of targeting ability. Here, we developed two types of targeting polymer micelles to separately deliver R837 and the anticancer drug doxorubicin (DOX) to TAMs and tumor cells via intratumoral injection and intravenous injection, respectively, for enhanced cancer chemo-immunotherapy against breast cancer. After these micelles accumulated in the tumor tissues, the immunostimulating micelles released R837, which bound to the TLR-7 receptor on the lysosomal membrane within the TAM, stimulating the maturation of the TAM, thereby causing an antitumor immune response and relieving the immunosuppressive effect in the tumor microenvironment. Simultaneously, the chemotherapeutic micelles released DOX in the cytoplasm of the tumor cells, directly inducing cell death. As a result, a synergistic combination of chemotherapy and immunotherapy was achieved through these nanomedicines, which separately activated the antitumor immune response and inhibited tumor cell growth. Therefore, this strategy is a new avenue for the development of targeting nanomedicines for combination chemo-immunotherapy against malignant cancer.

更新日期：2019-10-16

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南